安德克萨内特阿尔法治疗XA因子抑制剂的重大出血的最终研究报告
Truman J Milling1, Saskia Middeldorp2, Lizhen Xu3
1Seton Dell Medical School Stroke Institute, Dell Medical School, University of Texas at Austin (T.J.M.).
Circulation
|February 21, 2023
概括
在发生严重出血的患者中,安德克萨尼特α有效地逆转了Xa因子 (FXa) 抑制剂. 在80%的患者中,该抗药显示出良好的或出色的止血效果,显著降低了FXa活性.
科学领域:
- 药理学
- 血液学
- 临床医学
背景情况:
- 安德xanet alfa是一种改性复合性非活性因子Xa (FXa),旨在逆转FXa抑制剂.
- 在ANNEXA-4研究中,对患有急性大出血的患者进行了评估.
- 这项研究提供了多中心前性阶段-3b/4研究的最终分析.
研究的目的:
- 在急性大出血患者中评估安德克萨内特α在逆转FXa抑制剂的疗效和安全性.
- 评估安德克萨尼阿尔法对抗FXa活性和血静效能的影响.
- 分析使用安德克桑特阿尔法治疗的患者的血栓事件和死亡率.
主要方法:
- 一个单一组队列研究招募了在FXa抑制剂服用后18小时内出现急性大出血的患者.
- 同主终点包括12小时后的抗FXa活性变化和静血疗效.
- 一个独立的评审委员会评估了出血标准,血静,血栓事件和死亡率.
主要成果:
- 在不同的FXa抑制剂 (apixaban,rivaroxaban,edoxaban,enoxaparin) 中,Andexanet alfa显著降低了抗FXa活性.
- 在80%的可评估患者中实现了良好的或优良的血液静止.
- 血栓事件发生在安全人群的10%;口服抗凝药重新启动后没有发生.
结论:
- 在患有严重出血的患者中,Andexanet alfa有效降低了抗FXa活性.
- 在大多数患者中,该药物表现出良好的或出色的止血效果.
- 在治疗与FXa抑制剂相关的出血并发症方面,Andexanet alfa具有显著的进步.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
15
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
15
Anticoagulant Drugs: Low-Molecular-Weight Heparins
809
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
809
Clot Retraction and Fibrinolysis
6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K


